# Abeona Therapeutics Inc.: overview ABEO · Nasdaq · CIK 318306 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/abeo.md) · [Financials](/companies/abeo/financials.md) · [Filings](/companies/abeo/filings.md) · [Insiders](/companies/abeo/insiders.md) Latest reported revenue: [$11.4m](/filings/0001493152-26-037576.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-037576). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | [0.4](/filings/0001493152-26-037576.md) | [0.0 d](/filings/0001493152-25-021723.md) | [5.4 d](/filings/0001493152-26-010413.md) | [8.7](/filings/0001493152-26-022614.md) | [11.4](/filings/0001493152-26-037576.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | [(5698.0%)](/filings/0001493152-26-037576.md) | not reported | [(422.7%) d](/filings/0001493152-26-010413.md) | [(264.1%)](/filings/0001493152-26-022614.md) | [(120.0%)](/filings/0001493152-26-037576.md) | | Net margin | % | not reported | not reported | not reported | [27208.3%](/filings/0001493152-26-037576.md) | not reported | [(377.5%) d](/filings/0001493152-26-010413.md) | [(195.8%)](/filings/0001493152-26-022614.md) | [(177.4%)](/filings/0001493152-26-037576.md) | | Diluted EPS | $ per share | [(0.63)](/filings/0001493152-25-021723.md) | not reported | [(0.24)](/filings/0001493152-26-022614.md) | [1.71](/filings/0001493152-26-037576.md) | [(0.10)](/filings/0001493152-25-021723.md) | not reported | [(0.30)](/filings/0001493152-26-022614.md) | [(0.35)](/filings/0001493152-26-037576.md) | | Free cash flow | $m | [(12.6) d](/filings/0001493152-25-021723.md) | [(17.2) d](/filings/0001493152-26-010413.md) | [(19.8)](/filings/0001493152-26-022614.md) | [(21.7) d](/filings/0001493152-26-037576.md) | [(23.7) d](/filings/0001493152-25-021723.md) | [(19.1) d](/filings/0001493152-26-010413.md) | [(20.7)](/filings/0001493152-26-022614.md) | [(18.0) d](/filings/0001493152-26-037576.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [3.0](/filings/0001493152-23-009381.md) | [1.4](/filings/0001493152-24-010190.md) | [3.5](/filings/0001493152-25-010978.md) | not reported | [5.8](/filings/0001493152-26-010413.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(2994.5%)](/filings/0001493152-23-009381.md) | [(3600.8%)](/filings/0001493152-24-010190.md) | [(1346.7%)](/filings/0001493152-25-010978.md) | not reported | [(1536.9%)](/filings/0001493152-26-010413.md) | | Net margin | % | [(2831.2%)](/filings/0001493152-23-009381.md) | [(2807.4%)](/filings/0001493152-24-010190.md) | [(1548.2%)](/filings/0001493152-25-010978.md) | not reported | [1223.1%](/filings/0001493152-26-010413.md) | | Diluted EPS | $ per share | [(0.86)](/filings/0001493152-22-008259.md) | [(5.53)](/filings/0001493152-24-010190.md) | [(2.53)](/filings/0001493152-25-010978.md) | [(1.55)](/filings/0001493152-26-010413.md) | [1.01](/filings/0001493152-26-010413.md) | | Free cash flow | $m | [(69.8)](/filings/0001493152-23-009381.md) | [(43.6)](/filings/0001493152-24-010190.md) | [(37.3)](/filings/0001493152-25-010978.md) | [(58.5)](/filings/0001493152-26-010413.md) | [(84.3)](/filings/0001493152-26-010413.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/abeo/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $31.7m | 5,136,490 | | Added +123,438 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $31.7m | 5,136,490 | | Added +123,438 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $20.7m | 3,352,474 | | Added +156,944 | | [Cable Car Capital, LP](/funds/1699575.md) | 2026-06-30 | $18.6m | 3,007,329 | | Unchanged | | [AIGH Capital Management LLC](/funds/1835943.md) | 2026-06-30 | $18.5m | 2,987,000 | | Reduced −113,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $13.7m | 2,211,433 | | Added +46,582 | | [OneDigital Investment Advisors LLC](/funds/1690370.md) | 2026-06-30 | $10.2m | 1,653,024 | | New +1,653,024 | | [AWM Investment Company, Inc.](/funds/1535264.md) | 2026-06-30 | $9.2m | 1,486,130 | | Added +683,000 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $7.8m | 1,261,090 | | Added +51,293 | | [KENNEDY CAPITAL MANAGEMENT LLC](/funds/884589.md) | 2026-06-30 | $7.7m | 1,240,071 | | Reduced −23,440 | ## Recent filings [All 987 filings](/companies/abeo/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 14:38 ET | [SCHEDULE 13D](/filings/0001477932-26-006433.md) | Ownership report, active investor | 0001477932-26-006433 | | 2026-09-15 | 12:00 ET | [8-K](/filings/0001493152-26-042702.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-042702 | | 2026-08-13 | 07:30 ET | [10-Q](/filings/0001493152-26-037576.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037576 | | 2026-08-13 | 07:30 ET | [8-K](/filings/0001493152-26-037575.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-037575 | | 2026-06-12 | 16:30 ET | [8-K](/filings/0001493152-26-028458.md) | 5.07 Shareholder vote results | 0001493152-26-028458 | | 2026-06-12 | 07:30 ET | [8-K](/filings/0001493152-26-028369.md) | 5.02 Departure or appointment of officers or directors | 0001493152-26-028369 | | 2026-06-10 | 16:15 ET | [8-K](/filings/0001493152-26-028106.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-028106 | | 2026-06-04 | 07:30 ET | [8-K](/filings/0001493152-26-027197.md) | 8.01 Other events | 0001493152-26-027197 | | 2026-05-13 | 07:35 ET | [10-Q](/filings/0001493152-26-022614.md) | Quarterly report, period 2026-03-31 | 0001493152-26-022614 | | 2026-05-13 | 07:30 ET | [8-K](/filings/0001493152-26-022610.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-022610 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-010413.md), filed Mar 17, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e843f82c-5510-40a2-9a46-780e2ecd9abf) ## About the filer - CIK: 318306 - Tickers: ABEO - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.